One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
